News

In this trial of over 500 patients, ALO-01 demonstrated significant pain relief. This primary endpoint was agreed to by the FDA via the special protocol assessment process. The

Although the drug is not approved for children, the company said that the FDA has granted the patent extension in recognition of its Arimidex pediatric studies. AstraZeneca had

This patent approval follows Delcath’s recent and successful efforts to extend its patent protection broadly in Europe and Asia. The company has expanded and updated its overseas portfolio

Purchasers will also receive warrants to purchase an aggregate of 1.39 million shares of common stock. The five-year warrants will be exercisable at an exercise price of $2.10

At the time of the analysis, dose levels tested ranged from 0.0005 to 0.030mg/m2 per day, respectively. Among the 15 evaluable patients at dose levels of 0.015 and

Coprexa is an oral, small-molecule, anti-copper agent that is highly specific for the reduction of free copper in serum, the most toxic form of copper in the body,

Other data from randomized Phase II and III studies involving Erbitux have demonstrated consistently high response rates and an up to three-fold higher rate of liver metastases resection

The randomized, multicenter Phase III pivotal clinical trial will compare SP1049C plus best supportive care (BSC) versus BSC alone for the treatment of patients with advanced adenocarcinoma of

The purpose of this study, aside from assessing general immune response and safety, was to compare cardiac safety in the different study groups following vaccination with Imvamune. Moreover,